PHARMO Institute, part of Lumanity

🤝 We are excited to announce a new strategic partnership between the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University & PHARMO Institute, part of Lumanity! Today, Prof. Marcel Bouvy (Utrecht University) and Dr. Naomi Boxall (PHARMO) signed an agreement that marks the beginning of an important collaboration in real-world data research. This partnership combines PHARMO's renowned real-world data capabilities with Utrecht University division's extensive expertise in pharmacoepidemiology. Together, we'll enhance our ability to: 📊 Conduct cutting-edge drug research using real-world data 🔍 Generate valuable insights into medicine safety and effectiveness 🎓 Create new research opportunities for scientists at both organizations 🌍 Drive innovation in healthcare through evidence-based research This collaboration aligns perfectly with our joined mission to improve the safe and effective use of medicines by patients and society through multidisciplinary research and knowledge dissemination. Looking forward to the impactful work we'll accomplish together! #Pharmacoepidemiology #RealWorldData #Research #Healthcare Utrecht University PHARMO Institute, part of Lumanity

Happy New Year to all of our passionate, collaborative, and enthusiastic clients, staff, and followers. We are excited for the start of the new year and look forward to working with all of you in 2025! #NewYears #NewYears2025 #HappyNewYear

Season's greetings from everyone at the PHARMO Institute, part of Lumanity. We wish you and your loved ones a peaceful, bright, and joyous holiday season.

The relationship between post-menopausal bleeding (PMB) and COVID-19 vaccination has been a topic of debate, with mixed conclusions from various studies. PMB can arise from multiple causes, including low estrogen levels or serious conditions like cervical cancer; vaccines can have a temporary influence on hormone levels, raising questions about their role in bleeds. A self-controlled cohort study in the Netherlands combined data from the CIMS vaccination registry, PHARMO’s GP data, and GP data from Nivel. The analysis included data of 692,760 women over 50 years of age. These women were followed for one-month post-vaccination to monitor GP consultations for PMB and compared with GP consultations recorded outside that period. The study considered various factors such as: • Vaccine type (mRNA vs. vector) • Vaccine brand (Pfizer/BioNTech, Moderna, AstraZeneca, Janssen) • Number of injection(s) (1st, 2nd, and 3rd doses) The study found no increase in GP consultations for PMB following COVID-19 vaccination among the women, providing valuable insights and reassurance regarding the safety of COVID-19 vaccines for postmenopausal women and highlights the usefulness of the PHARMO Data Network in monitoring safety events following vaccine exposure. Speak to the research team at the PHARMO Institute to learn about our capabilities in designing post-authorization safety studies for vaccines and read more about the study at https://buff.ly/4gcpp42 #COVID19 #womenshealth #menopause #PMB #PostMenopausalBleeding #Pharmacovigilance #Pharmacoepidemiology #RWD #RWE

Duchenne’s Muscular Dystrophy (DMD) and Beckers Muscular Dystrophy (BeMD) have a global prevalence of 0.0048% and 0.001%, respectively. Due to the rarity of these conditions, and the multi-disciplinary nature of care management, identifying these patients in real world data (RWD) can be challenging. Uncertainties in the long-term safety of novel treatments for DMD/BeMD, such as cell and gene therapies, further increase demand for robust, longitudinal real world data within these disease populations. We deliver research insights into DMD and BeMD and our network offers great research potential for these rare disease populations: • 20+ years of follow up across multiple patient healthcare settings • ~199 patients identified with DMD and ~245 with BeMD diagnosis within the General Practitioner (GP) database between 2003-2023 • Clinical laboratory data to identify the target cohort via creatine kinase concentration testing and deeper insights into the genetic makeup of patients via the pathology registry Our RWD is available to address a wide range of use cases from treatment patterns, disease progression, safety, and validation of surrogate endpoints of your trial. We invite you to put our data to the test. Learn more about our expertise at https://buff.ly/4eMA5Fs or email us at pharmo@pharmo.com to discuss your real world evidence research needs. #raredisease #duchennes #beckers #RWE #RWD #realworlddata #SIGMAconsortium #ENCEPP #safetystudies #longitudinaldata

In case you missed it, we recently discussed the use of real world data to guide precision oncology drug development . The discussion featured the topics of: - Strategic challenges in precision oncology - Approaches for navigating these uncertainties - The role of real world data and analytics and whether the use of real world evidence can be optimized to close gaps in target identification/biomarker discovery, indication prioritization, and disease & market understanding. Watch the recording of the webinar at https://buff.ly/3Z9eH8T  #RWE #RWD #Oncology #DrugDevelopment #PrecisionOncology #RealWorldEvidence #RealWorldData #Biomarket #Cancer

We're having a great conference so far at #ISPOREU! Be sure to catch our poster on display, Identifying and Profiling Patients With Heart Failure in a Population-Based Cohort Through Linkage of Primary and Secondary Care Data, and reach out to connect with Josine Kuiper, Senior Business Development Manager, Real World Evidence if you're in Barcelona. #RWE #RWD #HEOR #ISPOR #HeartFailure #SecondaryCareData #PrimaryCareData

It's not too late to register for tomorrow's webinar focusing on how leveraging real world data can illuminate the path to successful biomarker discovery and targeted drug development. Register at https://lnkd.in/ejpbAj7a Featuring: - Eleonora Iob, PhD, Research Manager, PHARMO Institute, part of Lumanity - Dennis Chang, PhD, SVP, Strategy Consulting, Lumanity - Keith Flaherty, MD, Director of Clinical Research at the Massachusetts General Hospital Cancer Centre and Professor of Medicine at Harvard Medical School - Siraj A., MD, Global Vice President, Translation Medicine, Lunit - Saurabh Sewak, PhD, Vice President, Corporate and Business Development, Foghorn Therapeutics #PrecisionOncology #RealWorldData #DrugDevelopment #Oncology #RWE #RWD

Discover how leveraging real world data can illuminate the path to successful biomarker discovery and targeted drug development by attending our upcoming webinar. Register at https://lnkd.in/eYNiJmn2 Featuring: - Eleonora Iob, PhD, Research Manager, PHARMO Institute, part of Lumanity - Dennis Chang, PhD, SVP, Strategy Consulting, Lumanity - Keith Flaherty, MD, Director of Clinical Research at the Massachusetts General Hospital Cancer Centre and Professor of Medicine at Harvard Medical School - Siraj A., MD, Global Vice President, Translation Medicine, Lunit #PrecisionOncology #RealWorldData #DrugDevelopment #Oncology #RWE #RWD

Iron deficiency is a principal contributor to anemia, but how it is measured and diagnosed can vary in routine clinical practice. New research leveraging results from the PHARMO Data Network’s general practitioner (GP) database and 4 clinical laboratories across the Netherlands highlights significant variation in the percentage of ferritin concentration measurements classified as abnormal, risking misdiagnosis, and incorrect treatment for patients with iron-related disorders. Between the 18 GPs investigated, the percentage of patients with low classification ferritin reference intervals ranged from 33-89% % in pre-menopausal women, 7-47 % in postmenopausal women and 8-28% in men, pointing to potential discrepancies in the diagnosis of iron-related disorders, depending on which GP a patient visits.   This study emphasises a critical issue, stemming from lack of harmonization in ferritin reference measurements, and an urgency to improve standardization across clinical decision makers. For researchers, these findings suggest that – when working with laboratory data – cutoff values for diagnoses may benefit from accounting for population differences and individual characteristics such as age, sex, menopausal status, and ethnicity, as well as exploring measurements that are outside the reference intervals of each laboratory. This approach can strengthen real world evidence study designs by ensuring clinically meaningful cohort selection and analysis interpretation.   Read the full publication at https://lnkd.in/dXGr4Yha and reach out to our research team at the PHARMO Institute at pharmo@pharmo.com to learn more.   #IronDeficiency #Ferritin #RWE #RWD #RealWorldData #RealWorldEvidence #ClinicalLabs #LabData #DecisionMaking